FDA-cleared profile

Rapid Neuro3D

iSchemaView, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Rapid Neuro3D analyzes adult head-and-neck CTA DICOM from the aortic arch to the vertex, removing bone, tissue, and venous vessels to generate 3D/2D neurovascular visualizations, including MIP, volume-rendered, and CPR views of carotid and vertebral arteries for trained physicians' lesion review and planning; results are not standalone clinical decisions.

Clinical role
Automated head-and-neck arterial visualization and segmentation to support physician confirmation of identified lesions, evaluation, documentation, follow-up, and treatment planning; output does not replace clinical assessment.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Excessive motion or metal implants may affect output. The module excludes inadequate intracranial arterial contrast, cone-beam C-arm CT, non-axial or non-supine series, missing or improperly ordered slices, and CTA datasets outside its stated field-of-view and acquisition constraints. Results are not intended for standalone clinical decision-making.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Rapid Neuro3D analyzes adult head-and-neck CTA DICOM from the aortic arch to the vertex, removing bone, tissue, and venous vessels to generate 3D/2D neurovascular visualizations, including MIP, volume-rendered, and CPR views of carotid and vertebral arteries for trained physicians' lesion review and planning; results are not standalone clinical decisions.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Conventional adult CTA DICOM images extending from the aortic arch to the vertex of the head.
  • Who uses it?Intended users: Physicians and trained clinical professionals evaluating neurovascular CTA; the physician remains responsible for clinical assessment and decisions.
  • What does the software produce?Output: A DICOM series with 3D rotational maximum-intensity projections, volume renders, source-series-equivalent images with bone/tissue/vein removal, and curved planar reformations of isolated left and right internal carotid and vertebral arteries.
  • What is its most important limitation?Key limitation: Excessive motion or metal implants may affect output. The module excludes inadequate intracranial arterial contrast, cone-beam C-arm CT, non-axial or non-supine series, missing or improperly ordered slices, and CTA datasets outside its stated field-of-view and acquisition constraints. Results are not intended for standalone clinical decision-making.

Clinical takeaway. Clinical role: Rapid Neuro3D analyzes adult head-and-neck CTA DICOM from the aortic arch to the vertex, removing bone, tissue, and venous vessels to generate 3D/2D neurovascular visualizations, including MIP, volume-rendered, and CPR views of carotid and vertebral arteries for trained physicians' lesion review and planning; results are not standalone clinical decisions.

Evidence takeaway. Evidence from the reviewed source record: K243350 FDA evidence is manufacturer-submitted standalone regulatory validation. The quality endpoint used 120 CTA cases from 115 patients, while the accuracy endpoint used 50 CTA cases from 48 patients; their totals are kept separate. No independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Rapid Neuro3D analyzes adult head-and-neck CTA DICOM from the aortic arch to the vertex, removing bone, tissue, and venous vessels to generate 3D/2D neurovascular visualizations, including MIP, volume-rendered, and CPR views of carotid and vertebral arteries for trained physicians' lesion review and planning; results are not standalone clinical decisions.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Automated head-and-neck arterial visualization and segmentation to support physician confirmation of identified lesions, evaluation, documentation, follow-up, and treatment planning; output does not replace clinical assessment.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Conventional adult CTA DICOM images extending from the aortic arch to the vertex of the head.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
A DICOM series with 3D rotational maximum-intensity projections, volume renders, source-series-equivalent images with bone/tissue/vein removal, and curved planar reformations of isolated left and right internal carotid and vertebral arteries.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult neurovascular CTA review, lesion documentation, follow-up, and treatment-planning workflows using a DICOM viewer, clinical workstation, or PACS.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Physicians and trained clinical professionals evaluating neurovascular CTA; the physician remains responsible for clinical assessment and decisions.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
Excessive motion or metal implants may affect output. The module excludes inadequate intracranial arterial contrast, cone-beam C-arm CT, non-axial or non-supine series, missing or improperly ordered slices, and CTA datasets outside its stated field-of-view and acquisition constraints. Results are not intended for standalone clinical decision-making.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243350 FDA evidence is manufacturer-submitted standalone regulatory validation. The quality endpoint used 120 CTA cases from 115 patients, while the accuracy endpoint used 50 CTA cases from 48 patients; their totals are kept separate. No independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243350 FDA evidence is manufacturer-submitted standalone regulatory validation. The quality endpoint used 120 CTA cases from 115 patients, while the accuracy endpoint used 50 CTA cases from 48 patients; their totals are kept separate. No independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

MIP clinical agreement

0.998 proportion

  • EndpointExpert-consensus agreement with source DICOM for 3D rotational MIP output
  • Population120 CTA cases from 115 patients; 1,920 MIP, VR, and SSE segments were evaluated across the quality study
  • Tested versionRapid Neuro3D configuration described in K243350

Volume-rendered clinical agreement

0.986 proportion

  • EndpointExpert-consensus agreement with source DICOM for volume-rendered output
  • Population120 CTA cases from 115 patients; quality study
  • Tested versionRapid Neuro3D configuration described in K243350

Source-series-equivalent clinical agreement

1 proportion

  • EndpointExpert-consensus agreement with source DICOM for source-series-equivalent output
  • Population120 CTA cases from 115 patients; quality study
  • Tested versionRapid Neuro3D configuration described in K243350

CPR clinical agreement

1 proportion

  • EndpointExpert-consensus agreement with source DICOM for curved planar reformation output
  • Population120 CTA cases from 115 patients; 480 CPR segments were evaluated in the quality study
  • Tested versionRapid Neuro3D configuration described in K243350

Extracranial segmentation Dice

0.89 Dice coefficient

  • EndpointAverage extracranial segmentation Dice versus ground truth
  • Population50 CTA cases from 48 patients in the segmentation-accuracy study
  • Tested versionRapid Neuro3D configuration described in K243350

Intracranial segmentation Dice

0.97 Dice coefficient

  • EndpointAverage intracranial segmentation Dice versus predicate-device reference
  • Population50 CTA cases from 48 patients in the segmentation-accuracy study
  • Tested versionRapid Neuro3D configuration described in K243350

Extracranial Hausdorff distance

0.44 mm

  • EndpointAverage Hausdorff distance between extracranial module output and ground truth
  • Population50 CTA cases from 48 patients in the segmentation-accuracy study
  • Tested versionRapid Neuro3D configuration described in K243350

Intracranial Hausdorff distance

0.44 mm

  • EndpointAverage Hausdorff distance between intracranial module output and predicate-device reference
  • Population50 CTA cases from 48 patients in the segmentation-accuracy study
  • Tested versionRapid Neuro3D configuration described in K243350

CPR centerline Hausdorff distance

0.31 mm

  • EndpointAverage centerline Hausdorff distance for CPR visualization
  • Population50 CTA cases from 48 patients in the segmentation-accuracy study
  • Tested versionRapid Neuro3D configuration described in K243350

K243350 Rapid Neuro3D segmentation-quality validation

  • DesignStandalone performance validation comparing MIP, volume-rendered, source-series-equivalent, and CPR outputs with source DICOM and expert consensus.
  • Population120 CTA cases from 115 patients (104 US, 16 OUS; 65 female and 50 male; ages 27 to 90+); major CT scanner manufacturers were represented and the dataset was independent of model-training data per internal quality-control processes.
  • Scopeexact submission
  • Tested versionRapid Neuro3D configuration described in K243350
  • Samplen=120
  • IndependenceSponsor or vendor study

K243350

Manufacturer-submitted FDA evidence; this is not an independent clinical-outcome study.

K243350 Rapid Neuro3D segmentation-accuracy validation

  • DesignStandalone performance validation comparing 3D visualization segmentation with ground truth or predicate reference and CPR centerlines with ground truth.
  • Population50 CTA cases from 48 patients (43 US, 7 OUS; 24 female and 24 male; ages 27 to 90+), assessed for extracranial and intracranial regions and CPR centerline accuracy.
  • Scopeexact submission
  • Tested versionRapid Neuro3D configuration described in K243350
  • Samplen=50
  • IndependenceSponsor or vendor study

K243350

Manufacturer-submitted FDA evidence; the intracranial comparison used the predicate-device reference for the stated endpoint.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K243350. This is not a comprehensive safety clearance and does not exclude family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Conventional adult CTA DICOM images extending from the aortic arch to the vertex of the head.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243350: Rapid Neuro3D

  2. Routing

    Source context, not route validation: The Rapid Platform accepts DICOM images and returns processed DICOM images to the source imaging modality or PACS; the resulting DICOM series can be used by DICOM viewers and clinical workstations. Local routing, identifiers, viewer behavior, and failure handling require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243350: Rapid Neuro3D

  3. AI processing

    Source context, not route validation: The exact Rapid Platform may be installed on-premises behind the customer firewall or in a hybrid on-premises/cloud configuration, on dedicated hardware or a virtual machine; the reviewed sources do not establish the current site-specific topology, storage, retention, availability, or service-level arrangement.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243350: Rapid Neuro3D

  4. Returned objects

    Source context, not route validation: A DICOM series with 3D rotational maximum-intensity projections, volume renders, source-series-equivalent images with bone/tissue/vein removal, and curved planar reformations of isolated left and right internal carotid and vertebral arteries.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243350: Rapid Neuro3D

  5. Viewer/worklist/report

    Unresolved route: A DICOM series with 3D rotational maximum-intensity projections, volume renders, source-series-equivalent images with bone/tissue/vein removal, and curved planar reformations of isolated left and right internal carotid and vertebral arteries.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243350: Rapid Neuro3D

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact Rapid Platform may be installed on-premises behind the customer firewall or in a hybrid on-premises/cloud configuration, on dedicated hardware or a virtual machine; the reviewed sources do not establish the current site-specific topology, storage, retention, availability, or service-level arrangement.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The Rapid Platform accepts DICOM images and returns processed DICOM images to the source imaging modality or PACS; the resulting DICOM series can be used by DICOM viewers and clinical workstations. Local routing, identifiers, viewer behavior, and failure handling require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-10-25

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Monitoring
Monitor CTA coverage and contrast eligibility, slice order and patient-position constraints, motion or metal-related failures, output review, DICOM delivery, failed or repeated analyses, reader overrides, downtime, updates, complaints, and exact-submission recalls.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Family CTA reconstruction outputs

RapidAI's current radiologist page lists automated CTA reconstruction for the head, neck, and aortic arch, with curved planar reformats, MIPs, volume renderings, bone removal, and segmentation. This is Rapid family context and does not establish the exact K243350 release or contract configuration.

product family · checked 2026-09-07

Rapid Platform DICOM exchange

The exact FDA submission describes DICOM input and return of processed DICOM images to the source modality or PACS; confirm local routing, viewer compatibility, firewall rules, and failure recovery during qualification.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243350
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, vendor product page, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or exact contract unit for K243350 was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The FDA indication requires trained clinical review, but no exact-version curriculum, competency assessment, or support terms were established.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K243350: Rapid Neuro3D

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid Neuro3D model card (K243350)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

  8. RapidAI for Radiologists: CTA reconstruction and neurovascular workflow

    RapidAI / iSchemaView - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, implementationCapabilities

  9. openFDA exact recall query for K243350

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K243350 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K200921

qER

Qure.ai Technologies

qER is a radiological computer aided triage and notification software indicated for use in the analysis of non-contrast head CT images. The device is intended to assist hospital networks and trained medical specialists in workflow triage by flagging the following suspected positive findings of pathologies in head CT images: intracranial hemorrhage, mass effect, midline shift and cranial fracture. qER uses an artificial intelligence algorithm to analyze images on a Stand-Alone Performance cloud-based application in parallel to the ongoing standard of care image interpretation.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-06-17
FDA-cleared K260406

Brainomix 360 Hyperdensity

Brainomix Limited

Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-06-12
FDA-cleared K253818

Annalise Enterprise

Harrison-AI Medical Pty, Ltd.

Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-03-03
FDA-cleared K251195

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-01-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history